Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 8

NCT ID: NCT00003604 Active, not recruiting - Kidney Cancer Clinical Trials

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery

Start date: October 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients with stage III or stage IV kidney cancer that has been removed by surgery.

NCT ID: NCT00003584 Active, not recruiting - Kidney Cancer Clinical Trials

Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

Start date: July 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Prednisone may help to relieve symptoms in patients with recurrent and/or metastatic kidney cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of vinorelbine and estramustine with or without prednisone in treating patients who have recurrent and/or metastatic kidney cancer.

NCT ID: NCT00003181 Active, not recruiting - Kidney Cancer Clinical Trials

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

Start date: May 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining chemotherapy with interleukin-2 and GM-CSF may be a more effective treatment for kidney cancer. PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2, vinblastine, and GM-CSF in treating patients with metastatic kidney cancer.

NCT ID: NCT00002847 Active, not recruiting - Kidney Cancer Clinical Trials

Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Start date: September 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system to try to stop cancer cells from growing. Combining interferon alfa and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer.

NCT ID: NCT00002846 Active, not recruiting - Kidney Cancer Clinical Trials

Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer

Start date: September 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2 in treating patients with metastatic or recurrent kidney cancer.

NCT ID: NCT00002589 Active, not recruiting - Kidney Cancer Clinical Trials

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Start date: July 1994
Phase: Phase 2
Study type: Interventional

RATIONALE: Treating a person's lymphocytes with interleukin-2 and monoclonal antibody may help them kill more cancer cells when they are put back in the body. PURPOSE: This phase II trial is studying how well lymphocyte therapy works in treating patients with stage III or stage IV kidney cancer.